Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

–Based on prespecified interim analysis condition, 120 patients are likely to lead sufficient events for interim analysis of progression-free survival (PFS) HANGZHOU and SHAOXING, China, Sept. 25, 2023 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) today announces the…